Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Since you must be the smartest on this (and on the other) board, let me ask you my question once again as no one volunteered to respond to the unwashed's inquiry:
A question for some best and the brightest on this board:
When am I going to be rich?
PS. Don't tell me "never" -- that's too obvious answer, even for me.
@wmtgreeter, and taking 2nd level exams for my 3rd GED this June (time flies, lol!)
Is it a coincidence that both ADXS and ONCS used Alliance Global Partners as an underwriter for their most recent secondaries. I think not, these two companies have something that connects them much more than can the public eyes see. What's that? Puzzling...
https://ir.advaxis.com/press-release/financial-news/advaxis-inc-announces-proposed-public-offering-common-stock
A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering.
Our former partner (Amgen) buys a small biotech (could have been us).
https://www.reuters.com/article/us-nuevolution-m-a-amgen/amgen-offers-to-buy-copenhagen-based-nuevolution-for-167-million-idUSKCN1SS0OC
(Reuters) - Amgen, the world’s largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.
Copenhagen-headquartered Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday.
Nuevolution has a patent protected drug research platform to identify small-molecule drug candidates to be taken as pills against cancer and inflammatory diseases.
I guess only with half a brain know that for sure. The other half responsible for cognitive thinking must be in a rudimentary state.
It's not about evil hedge funds. In the wild, the weakest and wounded are the primary targets for the predators, especially to those who hunt in packs. They single out the target, then hunt collectively. Maximum food with a minimal risk.
Same here with Advaxis -- the management has weakened this company to a state that we are technically in the ICU. The predatory hedgies have been raiding this company for years, and they are just waiting for a dead corpse. A miraculous resurrection is possible, but highly unlikely. No knight on a white horse is coming. Ahh, that was a catafalque coming...
No, you did not. I said, this board.
Any news about a CT failure has an implication of a BP getting desperate to replenish their pipeline. Nothing wrong with that. The question only is Advaxis on their radars? We have no idea, and so far the answer has been a resounding no.
It does not meant they are going to buy ADXS. How many times MRK/BMY/.../... had clinical failures and this board thought it would be Advaxis they'd buy immediately? Why this time it's going to be different? Meantime, MRK just spent 2.2B to buy Peloton Therapeutics
https://www.marketwatch.com/story/merck-to-acquire-peloton-therapeutics-for-upfront-payment-of-105-billion-in-cash-2019-05-21
Both have flaws, but based on my experience with several companies I follows, whalewisdom tends to be more accurate than fintel.
“. Cash: To me it is the only legitimate problem.”
————————————————————-
You got it wrong. The major and the most important problem is the management, or how the company has been mismanaged for years. The cash issue is the consequence of the mismanagement: cash burned on trials that were terminated without any fanfares, manufacturing facility, outlandish compensations and benefits, and etc and etc. I am. Or even sure if this management can resolve the cash issue albeit they cut the cash burn rate few months ago. Now it looks like the burn rate will be ramping up due to NEO and HOT. Sigh.
Companies routinely update on the enrollment completion status either via a PR or in 8-K. There are no SEC clauses to prohibit that. Advaxis is no different.
Once the enrollment is complete, they'll issue a PR. As there's not been a PR, we need to assume the full enrollment is not reached yet. The enrollment was suspended during the hold. Thus, we are four months late, at least.
I'll send you Whiskas Purrfectly Chicken Pouches Variety pack CATT/DOGG Food, case of 10, if we get a deal soon. Heard catts are even more sensitive than doggs and can predict the future.
Even though it’s apples to oranges, do you agree that the results are impressive? Very troubling that Advaxis had the data almost 4 years ago and we are still in square one. Iovance will be a leader in this area of the cervical cancer. As for the primary and the secondary outcome measures, Advaxis also had ORR. But it was not impressive and wasn’t pumped as the 12-months survival.
ADXS tech gets obsolete by hours.
They need to sell their tech to someone who can deliver the drugs to patients.
ADXS cervical cancer data no longer looks impressive.
When ADXS issued a PR in '15 about the cervical data, they touted the 52% improvement over "median" OS results, and reluctantly hid the overall response rates (ORR). Their ORR is as follows:
GOG 0265 data was: CR:=1; SD:=15, out of 50 patients. ORR:=32%
Now, IOVA presented data at ASCO:
"Preliminary results from a Phase 2 study, innovaTIL-04, assessing lead candidate LN-145 in patients with recurrent/metastatic/refractory cervical cancer (average of 2.6 prior lines of therapy) showed a 44% response rate (n=12/27) and a disease control rate (DCR) (responders + stable cancer) of 89% (n=24/27). 11 of the 12 responders maintained their responses at a median follow-up of 3 1/2 months. By comparison, the response rate for Merck's (NYSE:MRK) Keytruda in second-line cervical cancer is 14%"
You don't have to be Hovacre to figure out that the GOG data is weak now. This explains a drop today.
https://seekingalpha.com/news/3464495-iovance-28-percent-premarket-positive-til-data
The more I think, the more I convinced I get that Ken is preparing his golden parachute to jump the plane. Strike Two means a career death for him and he knows that very well. The fact that Petit has divorced from this dead corpse suggests that he's not alone. Other top managers will follow him. They will not have time to complete a reverse merger.
We are pennies away from the all time low of 2.73 made in mid December '18.
Now, someone is dumping big and shorting. Two killer forces.
I'd say that ADXS could be trying to raise another round of cash with some vultures, and that is leaked. The company has been trying to pump up the share price in their regular way via issuing fluff PRs. They provided an update on ADXS/PSA and NEO, and will be presenting at Tier 3 conference while skipping ASCO.
Ken is nervous as his salary and benefits could be ending soon as the company goes belly up.
Batermere,
Sorry to hear that. Many of us made the similar mistake 4 years ago including myself. I thought I could retire by 2022, but now it looks like I'd need 10 more years before I can afford retirement. It is depressing, but I have to keep going, there is no other choice. You get knocked down, just get up and fight. I detest people who used to sing sweet songs on the message boards like mythological sirens. I was reckless to listen to those predators. We all know those names. Some are still around.
I will never make this type of mistake, never again. Learned very hard way.
@wmtgreeter
As I said few times before, if I see Hudson Bay Capital participate in the secondary it would be literally a kiss of death -- I've seen that couple of times before. Now they are in:
HUDSON BAY CAPITAL MANAGEMENT LP 143,350 573 143,350 0.2055% 13F 2019-03-31 2019-05-15
Also, CVI and Dafna Capital Management both increased their shares. Looks like almost all of the shares from the most recent secondary are now accounted for.
CVI HOLDINGS, LLC 210,570 0.93 16 64,134 0.3019% 13F 2019-03-31 2019-05-15
DAFNA CAPITAL MANAGEMENT LLC 202,222 0.16 46 91,055 0.2900% 13F 2019-03-31 2019-05-15
If it bleeds red, it means we're still alive...
Exactly what I thought. We will be in a 3-3.35 trading range for a while until we get anything of a substance, either positive or negative. The lift itself is not a stock mover. Even an FDA approval of a modified AXAL trial will not move the needle as it implies the cash burn will be higher for two years or so -- not sustainable in any way. They need to sell or partner AXAL. Technically, ADXS can hardly support one single clinical trial, but they're running 4 now on my count. It's not sustainable at all. They'll be either forced to terminate 2 or 3 trials, or sell these at a big discount before this collapses pretty soon.
Any guesses where Petit could end up? Oncosec, anyone? That's where elephants go to die...
Trading resumed, and likely no more news pending. Up ~15% in PM, but I believe we'll make a round trip today. They will short this pop.
It's great, but there was no update on the status of the CT protocol modification for Aim2Cerv. Will FDA allow the change in the protocol?
This news will have little impact on the PPS. Even getting back to $4 is going to be problematic. We need a strong catalyst, not this lift.
From today's PR:
There are 16 patients in the combination therapy part of this trial who are alive and continue to be monitored.
It looks like 8 more patients have died since 2/1/19 (previous data readout), in about 3.5 months. The death rate has accelerated.
From April's CP:
The MOS was 21.1 months. Thus, just a marginal improvement is median OS compared to the next generation hormonal agents (NGHAs) if compared with the upper bound. Will that warrant a deal? We have seen this before with the best-in-class cervical cancer results, when there was some improvement. Nothing has happened. Are the results compelling enough for Merck to jump? Based on the non-response, I'd be surprised they would. Too much time has passed, and nothing has been signed. ADXS-COLD.
It's mind boggling that they skipped the ASCO conference and are presenting at Tier 3 conference. Were the abstracts rejected or they just missed the deadlines?
I'm pretty sure that the lawsuits will follow. Although most will target the BOD and the current top management, I'd like to see DOC and Lombardo in these lawsuits. The justice should be served if the criminal investigation is initiated against that J&E personality or the entity behind that scam.
The game is OVER. This company has been in a death spiral for over 20 months, and now very close to a singularity point. The collapse could happen either by going bankrupt or fire selling assets for a fraction of penny per dollar.
What news are you talking about?
Those who proclaimed "NEWS is coming soon" have left this board after their mission was accomplished. Give them a shout at the ONCS board.
The market cap dived below 25M for the first time in past few months. Not a good sign.
I am really puzzled about these three things:
1) A total silence regarding Aim2Cerv program. Why does it take so long to lift the hold and get the FDA approval for the clinical trial protocol. It does look like FDA and the company have too far apart from each other to get anything done before we hear a mezzo soprano from a fat lady.
2) Why HOT is still not partnered? There is no way in hell the company can run this HOT trial alone -- no cash, no expertise.
3) NEO. I do not think they can afford to run this trial alone. Even more expensive than the other two programs, and no clear way to move forward.
I personally expect they pull a plug on AXAL and NEO soon, and keep only HOT. Which means, Petit is going to quit (or, forced to quit). Something's in the air... Smells really bad.
You must have missed an obituary in the Princeton Gazette. Lombardo Funeral Home arranged an Advaxis funeral for 9/25/19. All former shareholders are invited.
Short interest dropped by almost 100K shares.
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
4/30/2019 267,461 195,916 1.365182
4/15/2019 363,485 1,944,594 1.000000
3/29/2019 246,026 294,593 1.000000
3/15/2019 207,099 186,814 1.108584
2/28/2019 155,359 29,369 5.289898
If it's posted on the company's FB page, why the hell the company does not refute the rumors? Very strange.
There is a smoke, there is a fire...
can you post the link?
Raja,
did you know that there is also Advaxis Pharmaceuticals in Mumbai?
https://www.linkedin.com/company/advaxis-pharmaceuticals/about/
(link to the company does not work, and since my Hindi and/or Marathi are non-existent, I cannot find any info about that company).
Maybe, just maybe, Sidranski/Berlin tandem has a plan to relocate to India and, therefore, Petit and Gutierrez have already moved there?
Did you just shake hands with Ken?
They will run out of money by mid-November this year if nothing is done by then. The cash runway could be shorter if the burn rate accelerates due to HOT and NEO. I'm puzzled why they could not partner HOT? Why the hell NEO is still un-partnered? Too many questions with too few answers from the management.